Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
This cross-sectional study assesses homologous recombination repair mutation genetic testing and associated characteristics among men with metastatic castration-resistant prostate cancer (mCRPC).
Listen to this episode from ESMO Podcasts on Spotify. ESMO Open Editor-in-Chief Giuseppe Curgliano introduces a discussion between Dr Sara Hurwitz, of the Fred Hutcinson…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.
The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.